Product Name:
SgK269-pY635
Product Number:
ab-pk811
Target Full Name: Tyrosine-protein kinase SgK269; Pseudopodium-enriched atypical kinase 1
Target Alias: FLJ21140; FLJ34483; PEAK1; KIAA2002 protein (partial sequence); SG269; Tyrosine-protein kinase SgK269: Sugen kinase 269
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK811
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y635
Protein UniProt: Q9H792
Protein SigNET: Q9H792
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human SgK269 (PEAK1) sequence peptide Cat. No.: PE-04AHC99
Antibody Immunogen Sequence: PNA(pY)DNL(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues P632 to L638; In the N-terminal half of the protein. This is the major in vivo phosphorylation site in SgK269.
Production Method: Corresponds to amino acid residues P632 to L638; In the N-terminal half of the protein. This is the major in vivo phosphorylation site in SgK269.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 190-210 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: Almost no significant cross-reactivities detected in A431 cells.
Related Product 1: SgK269-pY635 blocking peptide
Scientific Background: SgK269 (PEAK1, pseudopodium-enriched atypical kinase 1) is a protein-serine/threonine kinase of the Other group and NKF3 family. It appears to function in the regulation of cell spreading and migration on fibronectin substrates. In addition, SgK269 is predicted to either directly or indirectly affect the phosphorylation of cytoskeleton-associated proteins, such as MAPK1/ERK and PXN. SgK269 has been demonstrated to function downstream of eIF5A1 and eIF5A2, translation initiation factors that have been implicated in several forms of human cancer. For example, the expression of these factors is required for the growth of pancreatic ductal adenocarcinoma (PDAC) cells in vivo and their overexpression in mice models leads to enhanced PDAC cell growth and tumour formation. Downstream activity of PEAK1 is required for the PDAC growth promoting effects of the eIF5A factors, indicating a role for SgK269 in the tumourigenesis of PDAC.
